Rasagiline in treatment of Parkinson’s disease

References

• AkaoYMaruyamaWYiHAn anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cellsNeurosci Lett2002326105812057839
   PubMed Web of Science ®Google Scholar
• BiglanKMRavinaBNeuroprotection in Parkinson’s disease:an elusive goalSemin eurol20072710612
   PubMed Web of Science ®Google Scholar
• BlackwellBMonoamine oxidase inhibitor interactions with other drugsJ Clin Psychopharmacol1991115592040717
   PubMed Web of Science ®Google Scholar
• BlandiniFArmenteroMTFancelluRNeuroprotective effect of rasagiline in a rodent model of Parkinson’s diseaseExp Neurol2004187455915144871
   PubMed Web of Science ®Google Scholar
• BraakHDel TrediciKRubUStaging of brain pathology related to sporadic Parkinson’s diseaseNeurobiol Aging20032419721112498954
   PubMed Web of Science ®Google Scholar
• ChenJJSwopeDMClinical pharmacology of rasagiline:a novel, second-generation propargylamine for the treatment of Parkinson diseaseJ Clin Pharmacol2005458789416027398
   PubMed Web of Science ®Google Scholar
• CollinsGGSandlerMWilliamsEDMultiple forms of human brain mitochondrial monoamine oxidaseNature1970225817205415111
   PubMedGoogle Scholar
• DemarcaidaJASchwidSRWhiteWBEffects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagilineMov Disord20062117162116856145
   PubMed Web of Science ®Google Scholar
• ElmerLSchwidSEberlySRasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptomsJ Neurol Sci2006248788316828804
   PubMed Web of Science ®Google Scholar
• FahnSDescription of Parkinson’s disease as a clinical syndromeAnn N Y Acad Sci200399111412846969
   PubMed Web of Science ®Google Scholar
• FialaKHWhetteckeyJManyamBVMalignant melanoma and levodopa in Parkinson’s disease:causality or coincidence?Parkinsonism Relat Disord20039321712853231
   PubMed Web of Science ®Google Scholar
• FinbergJPLamensdorfICommissiongJWPharmacology and neuroprotective properties of rasagilineJ Neural Transm Suppl199648951018988465
   PubMedGoogle Scholar
• FinbergJPTakeshimaTJohnstonJMIncreased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitorNeuroreport1998970379559942
   PubMed Web of Science ®Google Scholar
• FinbergJPWangJBankiewiczKIncreased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R (+)-N-propargyl-1-aminoindan (rasagiline) in the monkeyJ Neural Transm Suppl199852279859564628
   PubMedGoogle Scholar
• FowlerJSVolkowNDLoganJSlow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawalSynapse19941886937839316
   PubMed Web of Science ®Google Scholar
• FreedmanNMishaniEKrauszYIn vivo measurement of brain monoamine oxidase B (MAO-B activity after rasagiline treatment, using L-[11C]Deprenyl and positron emission tomography (PET)Movement Disorders2005S89P298
   Google Scholar
• GoetzCGSchwidSREberlySWSafety of rasagiline in elderly patients with Parkinson diseaseNeurology2006661427916682679
   PubMed Web of Science ®Google Scholar
• GoggiJTheofilopoulosSRiazSSThe neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in cultureNeuroreport20001139374111192605
   PubMed Web of Science ®Google Scholar
• GreenARMitchellBDTordoffAFEvidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamineBr J Pharmacol1977603439890205
   PubMed Web of Science ®Google Scholar
• HirschECHunotSFaucheuxBDopaminergic neurons degenerate by apoptosis in Parkinson’s diseaseMov Disord199914383510091646
   PubMed Web of Science ®Google Scholar
• HungAYSchwarzschildMAClinical trials for neuroprotection in Parkinson’s disease:overcoming angst and futility?Curr Opin Neurol2007204778317620885
   PubMed Web of Science ®Google Scholar
• KamakuraKMochizukiHKaidaKTherapeutic factors causing hallucination in Parkinson’s disease patients, especially those given selegilineParkinsonism Relat Disord2004102354215120098
   PubMed Web of Science ®Google Scholar
• LangAEThe progression of Parkinson disease:a hypothesisNeurology2007689485217372132
   PubMed Web of Science ®Google Scholar
• LangAEObesoJAChallenges in Parkinson’s disease:restoration of the nigrostriatal dopamine system is not enoughLancet Neurol200433091615099546
   PubMed Web of Science ®Google Scholar
• LauterbachECThe neuropsychiatry of Parkinson’s disease and related disordersPsychiatr Clin North Am2004278012515550293
   PubMed Web of Science ®Google Scholar
• LewittPANeuroprotection for Parkinson’s diseaseJ Neural Transm Suppl20061132217447422
   PubMedGoogle Scholar
• MandelSWeinrebOAmitTMechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivativesBrain Res Brain Res Rev2005483798715850677
   PubMed Web of Science ®Google Scholar
• MaruyamaWAkaoYCarrilloMCNeuroprotection by propargylamines in Parkinson’s disease:suppression of apoptosis and induction of prosurvival genesNeurotoxicol Teratol2002246758212200198
   PubMed Web of Science ®Google Scholar
• MaruyamaWAkaoYYoudimMBTransfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinolJ Neurochem2001787273511520893
   PubMed Web of Science ®Google Scholar
• MaruyamaWNittaAShamoto-NagaiMN-Propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factorNeurochem Int20044439340014687604
   PubMed Web of Science ®Google Scholar
• MontastrucJLChaumerliacCDesboeufKAdverse drug reactions to selegiline:a review of the French pharmacovigilance databaseClin Neuropharmacol200023271511154095
   PubMed Web of Science ®Google Scholar
• NaoiMMaruyamaWAkaoYInvolvement of type A monoamine oxidase in neurodegeneration:regulation of mitochondrial signaling leading to cell death or neuroprotectionJ Neural Transm Suppl2006677717447417
   PubMedGoogle Scholar
• O’CarrollAMFowlerCJPhillipsJPThe deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regionsNaunyn Schmiedebergs Arch Pharmacol19833221982026408492
   PubMed Web of Science ®Google Scholar
• OlanowCWRationale for considering that propargylamines might be neuroprotective in Parkinson’s diseaseNeurology200666S697916717254
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupEffect of deprenyl on the progression of disability in early Parkinson’s diseaseN Engl J Med19893211364712509910
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupEffects of tocopherol and deprenyl on the progression of disability in early Parkinson’s diseaseN Engl J Med1993328176838417384
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled trial of rasagiline in early Parkinson disease:the TEMPO StudyArch Neurol20025919374312470183
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled, randomized, delayed-start study of rasagiline in early Parkinson diseaseArch Neurol200461561615096406
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations:the PRESTO studyArch Neurol200562241815710852
   PubMed Web of Science ®Google Scholar
• RabeyJMSagiIHubermanMRasagiline mesylate, a new MAOB inhibitor for the treatment of Parkinson’s disease:a double-blind study as adjunctive therapy to levodopaClin Neuropharmacol2000233243011575866
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialLancet20053659475415766996
   PubMed Web of Science ®Google Scholar
• RichardIHKurlanRTannerCSerotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study GroupNeurology199748107079109902
   PubMed Web of Science ®Google Scholar
• RiedererPLachenmayerLLauxGClinical applications of MAOInhibitorsCurr Med Chem20041120334315279566
   PubMed Web of Science ®Google Scholar
• RiedererPYoudimMBMonoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenylJ Neurochem1986461359652420928
   PubMed Web of Science ®Google Scholar
• RitterJLAlexanderBRetrospective study of selegilineantidepressant drug interactions and a review of the literatureAnn Clin Psychiatry199797139167831
   PubMedGoogle Scholar
• ShultsCWTreatments of Parkinson disease:circa 2003Arch Neurol2003601680414676041
   PubMedGoogle Scholar
• SpeiserZLevyRCohenSEffects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disordersJ Neural Transm Suppl1998522873009564629
   PubMedGoogle Scholar
• SquiresRFMultiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability:a comparison of eight mammalian speciesAdv Biochem Psychopharmacol19725355705054207
   PubMedGoogle Scholar
• SternMBMarekKLFriedmanJDouble-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patientsMov Disord2004199162315300656
   PubMed Web of Science ®Google Scholar
• SternbachHThe serotonin syndromeAm J Psychiatry1991148705132035713
   PubMed Web of Science ®Google Scholar
• SuchowerskyODevriesJPossible interactions between deprenyl and prozacCan J Neurol Sci19901735232119870
   PubMed Web of Science ®Google Scholar
• TannerCMDopamine agonists in early therapy for Parkinson disease:promise and problemsJama20002841971311035895
   PubMed Web of Science ®Google Scholar
• ThebaultJJGuillaumeMLevyRTolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:a potent, selective, and irreversible monoamine oxidase type B inhibitorPharmacotherapy200424129530515628826
   PubMed Web of Science ®Google Scholar
• ToyamaSCIaconoRPIs it safe to combine a selective serotonin reuptake inhibitor with selegiline?Ann Pharmacother19942840568193438
   PubMed Web of Science ®Google Scholar
• WatersCHFluoxetine and selegiline – lack of significant interactionCan J Neurol Sci199421259618000982
   PubMed Web of Science ®Google Scholar
• WeinrebOAmitTBar-AmONovel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety:interaction of Bcl-2 family members with PKC pathwayAnn N Y Acad Sci200510533485516179541
   PubMed Web of Science ®Google Scholar
• YiHMaruyamaWAkaoYN-Propargylamine protects SHSY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2J Neural Transm2006113213215843867
   PubMed Web of Science ®Google Scholar
• YoudimMBThe advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reactionActa Psychiatr Scand Suppl1995386577717095
   PubMedGoogle Scholar
• YoudimMBBar AmOYogev-FalachMRasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transitionJ Neurosci Res200579172915573406
   PubMed Web of Science ®Google Scholar
• YoudimMBGrossAFinbergJPRasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBr J Pharmacol2001132500611159700
   PubMed Web of Science ®Google Scholar
• YoudimMBRiedererPFA review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s diseaseNeurology200463S32515477584
   PubMed Web of Science ®Google Scholar
• YoudimMBTiptonKFRat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline:its relationship to 2-phenylethylamine induced stereotypy and Parkinson’s diseaseParkinsonism Relat Disord200282475312039419
   PubMed Web of Science ®Google Scholar
• YoudimMBWadiaATattonWThe anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivoAnn N Y Acad Sci2001939450811462801
   PubMed Web of Science ®Google Scholar
• YoudimMBWeinstockMMolecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]Cell Mol Neurobiol2001215557312043833
   PubMed Web of Science ®Google Scholar